Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review

Current Atherosclerosis Reports

Volumn 15, Issue 3, 2013, Pages

  Nseir, William ^a   Mahamid, Mahmud ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b Israel   (Israel)

Author keywords

Hyperlipidemia; Metabolic syndrome; Statins; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PENTOXIFYLLINE; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; MORTALITY; NONALCOHOLIC FATTY LIVER; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; WEIGHT REDUCTION; DISEASE COURSE; FATTY LIVER; PROGNOSIS;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS;

MLCS; MLOWN;

EID: 84872196813     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0305-5     Document Type: Review

References (46)

1. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-40. (Pubitemid 34747534)
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8. (Pubitemid 10057164)
3. Angulo P. Nonalcoholic fatty liver diseases. N Eng J Med. 2002;346:1221-31.
4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-23. (Pubitemid 36397405)
5. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and metabolic syndrome. Curr Opin Lipidol. 2005;16:421-7. (Pubitemid 41017626)
6. Kral JG, Schaffner F, Pierson Jr RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548-51. (Pubitemid 23141622)
7. Assy N, Kaita K, Mymin D, Levy C, Roser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929-34.
8. Azzout-Marniche D, Bécard D, Guichard C, Foretz M, Ferré P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J. 2000;350:389-93.
9. Day CP, James OF. Steatohepatitis: a tale of two "hits". Gastroenterology. 1998;114:842-5.
10. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898-904. (Pubitemid 34258385)
11. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel II). Circulation. 1994;89:1333-445.
12. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439-49.
13. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272-3.
14. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large healthmaintenance organization. AmJMed. 2005;118:618-24. (Pubitemid 40732701)
15. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-65. (Pubitemid 43357551)
16. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:2579-88.
17. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51:918-24.
18. Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care. 2008;11:766-73.
19. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738. (Pubitemid 32113289)
20. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7:325-31.
21. • Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci. 2012;57:1773-81. This review describes all human studies that examined the safety and efficacy of the statins and other lipid-lowering agents in patients with NAFLD, and the mechanisms linking hyperlipidemia and fatty infiltration.
22. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753-61. (Pubitemid 44917301)
23. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes. 1984;33:333-8. (Pubitemid 14169533)
24. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
25. Halcox JP, Deanfield JE. Beyond The laboratory: clinical implications for statin pleiotropy. Circulation. 2004;109((21 Suppl 1):II 42-8.
26. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmol Sci. 2002;23:482-6. (Pubitemid 35279610)
27. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection. 2012;40:41-8.
28. Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, Mograbi J. Randomized clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate-placebo-controlled study. Aliment Pharmacol Ther. 2012;36:231-8.
29. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453-63. (Pubitemid 350155527)
30. Chalasani N, Aljadhey H, Kesteron J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;128:1287-92. (Pubitemid 38552793)
31. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62-5. (Pubitemid 40250595)
32. Abel T, Feher J, Dinya H, Eldin MG, Kovacs A. Safety and efficacy of combined ezetemibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit. 2009;15:MS6-MS11.
33. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990-4.
34. Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology. 2009;56:1117-21.
35. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174:193-6. (Pubitemid 38595458)
36. Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open - label, pilot study. Hepatol Res. 2011;41:1057-65.
37. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemidia, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23:1643-7. (Pubitemid 43727474)
38. •• Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver test in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376:1916-22. This RCT, which contained a large number of participants (437), showed that atorvastatin was safe and improved liver function in patients suspected to have NAFLD.
39. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713-8. (Pubitemid 38072335)
40. Athyros VG, Mikhaildis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Cur Med Res Opin. 2006;22:873-83. (Pubitemid 43875555)
41. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of preliminary study. J Gastrointestin Liver Dis. 2007;16:39-46. (Pubitemid 46548588)
42. Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45:750-7.
43. Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011;12:80-5.
44. • Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71-7. This subgroup study from the St. Francis RCT shows that the combination therapy of atorvastatin and vitamin C and E improved hepatic steatosis, as assessed by CT scan.
45. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006;184:233-4. (Pubitemid 41721093)
46. Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2012;42:1065-72.